Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...

In a Maple Grove industrial strip mall unequipped with the beanbag chairs common to Silicon Valley startups, Francis Medical is creating a device to treat prostate cancer, working with a remote ...

Francis Medical is heating up with a 510(k) clearance from the FDA for its water vapor ablation therapy aimed at cancers of the prostate, kidneys and bladder. The regulatory go-ahead for its Vanquish ...

Transurethral ablation of Gleason grade group 2 (GG2) lesions using water vapor therapy cleared the area of prostate cancer in 75% of men and 91% had no GG2 or higher-grade cancer remaining at 6 ...

MINNEAPOLIS, Dec. 2, 2025 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of ...

Francis Medical's Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug Administration (FDA). Vanquish is a transurethral, ultrasound and ...

Vanquish Water Vapor Ablation uses thermal energy stored in sterile water vapor to ablate targeted prostate tissue, conforming to the natural boundaries of the treated area potentially minimizing risk ...

MINNEAPOLIS, Feb. 3, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at ...

Industry trade associations made the case for revisions to draft guidance on clinical testing recommendations for prostate tissue ablation devices in comments earlier this month. The Medical Imaging & ...